Skanska awarded US biotech project worth USD 70 M, about SEK 445 M
Skanska USA Building has signed a contract with a leading Bay Area biotechnology company. The contract amounts to USD 70 M, about SEK 445 M, which will be included in order bookings for the second quarter 2011.
The scope of work will provide construction management. Skanska will also move services for the company’s campus in the region. Work will commence this summer and continue over a three year period.
Skanska USA is one of the leading development and construction companies in the country, consisting of four business units: Skanska USA Building, which specializes in building construction; Skanska USA Civil, specialized in civil infrastructure; Skanska Infrastructure Development, which develops public-private partnerships; and Skanska Commercial Development, which develops commercial development projects in select U.S. markets. Headquartered in New York, Skanska USA has approximately 7,400 employees and its 2010 revenues were SEK 34.3 billion.